gemcitabine has been researched along with naphthoquinones in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, FY; Fu, M; Liang, X; Lin, C; Yang, Y; Yao, J; Zhang, XY | 1 |
| Hong, SW; Hong, YS; Jin, DH; Jung, KA; Kim, KP; Kim, SM; Kim, TW; Lee, JL; Lee, JS; Shin, JS; Suh, C; Yoon, DH | 1 |
| Cheng, CC; Chiu, TH; Huang, YT; Lai, PC; Lin, TC | 1 |
| Han, B; Ji, L; Jia, G; Jiang, H; Li, Y; Liu, J; Lv, J; Pan, S; Song, Z; Sun, B; Teng, Y; Wang, Y; Zhou, Y | 1 |
| George, TJ; Liu, C; Lu, Z; Ostrov, DA; Puszyk, WM; Robertson, KD; Zhao, X | 1 |
| Beg, MS; Bolluyt, J; Boothman, DA; Deberardinis, RJ; Fattah, F; Gerber, DE; Huang, X; Laheru, D; Leff, R; Merritt, ME; Sarode, V; Silvers, MA; Xie, XJ | 1 |
| Ahn, DH; Bekaii-Saab, T; Goldstein, D; Li, CP; Macarulla, T; O'Neil, B; Okusaka, T; Reni, M; Sonbol, MB; Tabernero, J; Van Cutsem, E | 1 |
1 trial(s) available for gemcitabine and naphthoquinones
| Article | Year |
|---|---|
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
Topics: Administration, Oral; Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Multicenter Studies as Topic; Naphthoquinones; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic; Young Adult | 2019 |
6 other study(ies) available for gemcitabine and naphthoquinones
| Article | Year |
|---|---|
[The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line].
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Proteins; Naphthoquinones; Pancreatic Neoplasms; RNA, Messenger | 2005 |
The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Naphthoquinones; Pancreatic Neoplasms; RNA, Small Interfering; Survivin | 2012 |
Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Topics: Adenine; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Fragmentation; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Microtubule-Associated Proteins; Naphthoquinones; Proto-Oncogene Proteins c-bcl-2; Securin; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Urothelium | 2014 |
Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Microvessels; Naphthoquinones; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; Naphthoquinones; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Survivin; Xenograft Model Antitumor Assays | 2015 |
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; NAD(P)H Dehydrogenase (Quinone); Naphthoquinones; Paclitaxel; Pancreatic Neoplasms | 2017 |